Home » Regions » Global News » Applied BioMath, Syntimmune collaborate onautoimmune diseases

Applied BioMath, Syntimmune collaborate onautoimmune diseases

Monday, December 4, 2017

Applied BioMath, a provider in applying mechanistic modeling to drug research and development, announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune’s ongoing clinical trials. Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune’s lead drug candidate, SYNT001. The goal is to create a semi-mechanistic PK/PD model to support further advancement of Syntimmune’s clinical trials of SYNT001 in a broad variety of IgG-mediated autoimmune diseases, including ongoing trials in Warm Autoimmune Hemolytic Anemia, Pemphigus, and other clinical indications.

“Our collaboration with Applied BioMath will allow us to gain additional validation of SYNT001’s differentiated properties, particularly in regard to the dose level, dosing frequency, and planned subcutaneous administration of our promising lead compound. We anticipate this collaboration will allow us to best optimize FcRn inhibition in the context of therapeutic induction and maintenance, enabled by our deep understanding of the underlying biology,” said David de Graaf, Ph.D., CEO of Syntimmune. “Applied BioMath has a stellar track record in helping customers with similar objectives, and we look forward to leveraging their capabilities for our program.”

Applied BioMath’s MADI approach involves rigorous fit-for-purpose model development and optimization techniques to estimate model parameters and variability using proprietary algorithms and software. Top pharmaceutical and biotechnology companies leverage Applied BioMath’s MADI approach to accelerate their candidates to market and to de-risk their research and development (R&D) from early research through to clinical trials. “We look forward to supporting Syntimmune as they progress further into the clinic,” said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. “This is a critical stage in R&D where strategic questions benefit greatly from the support of MADI.”

Related Posts